New Novartis director will implement Bexsero on U.K. immunization program

Now that the U.K. has OK'd Novartis' ($NVS) meningitis B vaccine, Bexsero, as an addition to its national immunization plan, the Swiss company's vaccines unit has appointed a new director to help it get there. Dr. John Porter, formerly the U.K. medical team lead for Pfizer ($PFE), will become Novartis' medical affairs director for Northern Europe. "We believe that given his expertise, Dr. Porter will be closely involved with the implementation of Bexsero on the U.K. National Immunization Program, following the recent recommendation from the Joint Committee on Vaccination and Immunisation," company spokesman Eric Althoff told FierceVaccines in an email. More

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.